As CBD use rises, clinical trials needed to determine safety, efficacy in heart disease patients

As cannabidiol (CBD) use rises, high quality randomized clinical trials are needed to determine if anti-inflammatory benefits of CBD for heart disease seen in preclinical data will work in a real-world setting, according to research presented at ACC Latin America 2022 Together with CardioAcademic. A review of existing studies found no clinical recommendations can be made given current evidence. ACC Latin America 2022 Together with CardioAcademic will be held in Mexico City on September 9–10, 2022.

This article was originally published on

You may also be interested in:

Read More:

Lawyers Lookup